person

Henrik L.

Country
Sweden
Department
Blod- och Tumörsjukdomar, Sektionen för onkologi

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
82
Sites with multiple studies

Has run more than one trial at 82 of 299 partner sites.

Specializations

Triple Negative Breast Cancer Research

This investigator specializes in studying therapeutic approaches for triple negative breast cancer (TNBC), with particular focus on neoadjuvant and adjuvant treatment strategies. Their research encompasses evaluating treatment responses in locally advanced TNBC and investigating combinations of chemotherapy with novel therapeutic agents.

  • Neoadjuvant therapy assessment
  • Pathologic complete response evaluation
  • Early-stage TNBC treatment

HER2-Positive Breast Cancer Studies

The investigator conducts extensive research in HER2-positive breast cancer treatment modalities, including innovative approaches with targeted therapies. Their work encompasses both early-stage and metastatic HER2-positive disease, with particular attention to novel antibody-drug conjugates and imaging techniques.

  • Targeted therapy optimization
  • Treatment response monitoring
  • Molecular imaging applications

Hormone Receptor-Positive Disease

Research activities include investigating endocrine therapy strategies for hormone receptor-positive breast cancer. The investigator focuses on optimizing treatment duration and exploring novel therapeutic combinations, particularly in the context of extended adjuvant therapy.

  • Endocrine therapy optimization
  • Treatment sequencing strategies
  • Long-term therapeutic approaches

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.